TrialAnnals of the rheumatic diseases2023

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.

Jeffrey R Curtis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.